Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
04 avr. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic strokeData shows behavioral outcomes improvement at one month in model of...
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Sweden
31 mars 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD)Modulation of neuroinflammation may be synergistic to existing treatments in AD NEW...
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
28 mars 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological diseaseTiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with...
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
22 mars 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
21 mars 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
20 mars 2023 08h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
17 mars 2023 08h10 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Highlighted in Forbes Article
17 mars 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab
08 mars 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Illustrates that the immunological basis of the mechanism of action for intranasal foralumab is based on increasing production of naïve-like T cells and Tregs, while simultaneously decreasing the...
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
04 janv. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...